Free shipping on all orders over $ 500

Ulocuplumab

Cat. No. M24637

All AbMole products are for research use only, cannot be used for human consumption.

Ulocuplumab Structure
Synonym:

BMS 936564; MDX 1338

Size Price Availability Quantity
100ug USD 190 In stock
5mg USD 800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.

Human CXCR4/CD184 Romas cells were stained with ulocuplumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=5.915 nM.

Chemical Information
CAS Number 1375830-34-4
Storage Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles.
References

[1] David Sermer, et al. Clin Lymphoma Myeloma Leuk. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia

[2] Steven P Treon, et al. Blood. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

[3] Jorge J Castillo, et al. Hematology Am Soc Hematol Educ Program. Management of Waldenström macroglobulinemia in 2020

[4] Irene M Ghobrial, et al. Clin Cancer Res. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

[5] Manoj K Kashyap, et al. Oncotarget. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

Related CXCR Products
Plerixafor (AMD3100)

Plerixafor (AMD3100) is a CXCR4 chemokine receptor antagonist.

WZ 811

WZ811 is a highly competitive CXCR4 antagonist with oral activity. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated regulation of cAMP level (EC50=1.2 nM) and SDF-1-induced matrix glue invasion (EC50=5.2 nM) in cells.

Navarixin

Navarixin (SCH 527123) is a novel, selective CXCR2 receptor antagonist with IC50 of 3 nM. Navarixin (SCH 527123) has Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.

AMD3465 hexahydrobromide (AMD3465 )

AMD3465 hexahydrobromide(AMD3465 ) is an effective CXCR4 antagonist that inhibits 12G5 mAb in SupT1 cells. The IC50 values of CXCL12AF647 and CXCR4 were 0.75 nM and 18 nM, respectively. AMD 3465 also effectively inhibited X4 HIV replication (IC50, 1-10 nM), but not R5 HIV replication.

Plerixafor 8HCl

Plerixafor 8HCl (AMD3100 8HCl) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ulocuplumab, BMS 936564; MDX 1338 supplier, CXCR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.